Munich/London, November 1, 2021 – In its largest deal to date, AURELIUS today announces the acquisition of McKesson UK in a corporate carve-out from US healthcare company McKesson Corporation, Irving, Texas. The deal with an enterprise value of GBP 477 million will be completed by AURELIUS’ newly launched co-investment structure with AURELIUS European Opportunities Fund IV controlling a 70% stake and AURELIUS Equity Opportunities SE & Co. KGaA (ISIN: DE000A0JK2A8) controlling 30%. The transaction is expected to close in Q1 2022, subject to customary closing conditions, including receipt of required regulatory approvals.
Click here to read the press release
